Bavarian Nordic Spon (OTCMKTS:BVNRY)‘s stock had its “hold” rating reiterated by research analysts at Maxim Group in a report released on Friday, MarketBeat reports.

Bavarian Nordic Spon (OTCMKTS BVNRY) opened at 12.16 on Friday. The stock’s 50 day moving average is $11.70 and its 200 day moving average is $11.70. The company has a market cap of $1.15 billion and a price-to-earnings ratio of 31.75. Bavarian Nordic Spon has a 52-week low of $10.44 and a 52-week high of $22.70.

Bavarian Nordic Spon (OTCMKTS:BVNRY) last issued its earnings results on Friday, August 25th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.07). The firm had revenue of $58.68 million during the quarter, compared to the consensus estimate of $50.65 million. Bavarian Nordic Spon had a return on equity of 11.36% and a net margin of 15.48%.

COPYRIGHT VIOLATION NOTICE: “Bavarian Nordic Spon ‘s (BVNRY) “Hold” Rating Reaffirmed at Maxim Group” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.watchlistnews.com/maxim-group-downgrades-bavarian-nordic-bvnry-to-hold/1563451.html.

About Bavarian Nordic Spon

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings for Bavarian Nordic Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic Spon and related companies with Analyst Ratings Network's FREE daily email newsletter.